METHOD OF DIFFERENTIAL DIAGNOSTICS OF HYPERTONIC DISEASE (HD) OF II STAGE AND ITS TREATMENT Russian patent published in 2013 - IPC A61B10/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology. Cardio-respiratory synchronism (CRS) test is carried out. Results of the test are used to determine index of vagosympathetic interaction and index of regulatory status adequacy (IRSA). If IVSI is higher than 1.05, sympathicotonic version of HD of II stage is determined. If IVSI is higher than 0.95 and lower than 1.05, mixed version of vegetative status of HD of II stage is determined. If IVSI values are lower than 0.95, parasympathetic version of HD of II stage is determined. In each HD version 3 levels of regulatory-adaptive status (RAS) are determined. Low RAS is determined at IRSA values lower than 30, middle - at IRSA values higher than 31 but lower than 59, high - at IRSA higher than 60. β-blokers are administered to patients with sympathicotonic version of HD with low and middle RAS level. To specify possible transfer of patient's state into other type of vegetative status control of IVSI and IRSA indices is performed 1 time per 3 months. In case of sympaticotonic version of HD with high RAS level, beta-adrenoblockers are administered under IVSI and IRSA control monthly. In case of sympathicotonic version of HD of II stage with low and high levels of RAS inhibitors of angiotensin-converting enzyme (iACE) are administered under IVSI and IRSA control 1 time per 3 months. In case of high RAS, they are administered 1 time per 6 months. In case of parasympathetic version of HD of II stage with low RAS level, thiazide diuretics are administered and IVSI and IRSA control is carried out 1 time per 6 months. In case of high RAS level IVSI and IRSA are controlled 1 time per 3 months. In case of parasympathetic version of HD of II stage with low, middle and high RAS levels calcium antagonists are administered with IVSI and IRSA control 1 time per 9-12 months. In case of mixed version of HD of II stage with low, middle RAS levels, calcium antagonists are administered with IVSI and IRSA control 1 time per 6 months. In case of mixed version of HD of II stage with low and middle RAS levels inhibitors of angiotensin-converting enzyme are administered under IVSI and IRSA control 1 time per 3 months. If fact of change of regulation type into opposite is determined, drug therapy is altered or medication which produces opposite effect on vegetative status is added.

EFFECT: method makes it possible to determine individual state of vegetative nervous system and level of regulatory-adaptive status, administer individual therapy of HD of II stage and control direction of vegetative reactions by means of objective criteria, which makes it possible to increase reliability of individual diagnostics and selection of tactics of HD of stage II treatment, reduce terms for selection of individualised therapy, reduce terms of medical and social rehabilitation of patients, increase quality of patient's life, determine the most informative criteria for dynamic observation aimed at adequate correction of anti-hypertension therapy.

8 ex, 1 tbl